These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18636037)

  • 41. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
    Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
    Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
    J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.
    Tsai YC; Ho PY; Tzen KY; Tuan TF; Liu WL; Cheng AL; Pu YS; Cheng JC
    Mol Cancer Ther; 2015 Mar; 14(3):810-20. PubMed ID: 25589492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.
    Zerbe LK; Dwyer-Nield LD; Fritz JM; Redente EF; Shroyer RJ; Conklin E; Kane S; Tucker C; Eckhardt SG; Gustafson DL; Iwata KK; Malkinson AM
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):605-20. PubMed ID: 18030469
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.
    Scaltriti M; Verma C; Guzman M; Jimenez J; Parra JL; Pedersen K; Smith DJ; Landolfi S; Ramon y Cajal S; Arribas J; Baselga J
    Oncogene; 2009 Feb; 28(6):803-14. PubMed ID: 19060928
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
    Normanno N; Bianco C; De Luca A; Maiello MR; Salomon DS
    Endocr Relat Cancer; 2003 Mar; 10(1):1-21. PubMed ID: 12653668
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Targeted therapies. New hopes, new challenges].
    Barlési F
    Rev Mal Respir; 2008 Jun; 25(6):661-2. PubMed ID: 18772823
    [No Abstract]   [Full Text] [Related]  

  • 48. Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib.
    Hülsmann HJ; Rolff J; Bender C; Jarahian M; Korf U; Herwig R; Fröhlich H; Thomas M; Merk J; Fichtner I; Sültmann H; Kuner R
    Lung Cancer; 2014 Nov; 86(2):151-7. PubMed ID: 25240516
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
    Konecny GE; Pegram MD; Venkatesan N; Finn R; Yang G; Rahmeh M; Untch M; Rusnak DW; Spehar G; Mullin RJ; Keith BR; Gilmer TM; Berger M; Podratz KC; Slamon DJ
    Cancer Res; 2006 Feb; 66(3):1630-9. PubMed ID: 16452222
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sulforaphane, a natural component of broccoli, inhibits vestibular schwannoma growth in vitro and in vivo.
    Kim BG; Fujita T; Stankovic KM; Welling DB; Moon IS; Choi JY; Yun J; Kang JS; Lee JD
    Sci Rep; 2016 Nov; 6():36215. PubMed ID: 27805058
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.
    Gallagher-Colombo SM; Miller J; Cengel KA; Putt ME; Vinogradov SA; Busch TM
    Cancer Res; 2015 Aug; 75(15):3118-26. PubMed ID: 26054596
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
    J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
    Nielsen DL; Andersson M
    Ugeskr Laeger; 2007 Sep; 169(37):3085-7. PubMed ID: 17877954
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
    Goss GD; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Guclu S; Isla D; Min YJ; Morabito A; Ardizzoni A; Gadgeel SM; Fülöp A; Bühnemann C; Gibson N; Krämer N; Solca F; Cseh A; Ehrnrooth E; Soria JC
    JAMA Oncol; 2018 Sep; 4(9):1189-1197. PubMed ID: 29902295
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
    Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.
    Jacob A; Oblinger J; Bush ML; Brendel V; Santarelli G; Chaudhury AR; Kulp S; La Perle KM; Chen CS; Chang LS; Welling DB
    Laryngoscope; 2012 Jan; 122(1):174-89. PubMed ID: 22109824
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The genetic landscape and possible therapeutics of neurofibromatosis type 2.
    Ghalavand MA; Asghari A; Farhadi M; Taghizadeh-Hesary F; Garshasbi M; Falah M
    Cancer Cell Int; 2023 May; 23(1):99. PubMed ID: 37217995
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Research progress on non-surgical treatment of vestibular schwannomas].
    Xu M; Jiang Y; Yao Q; Yu D
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Dec; 36(12):971-976. PubMed ID: 36543410
    [No Abstract]   [Full Text] [Related]  

  • 59. Reduction of sporadic and neurofibromatosis type 2-associated vestibular schwannoma growth in vitro and in vivo after treatment with the c-Jun N-terminal kinase inhibitor AS602801.
    Dougherty MC; Shibata SB; Clark JJ; Canady FJ; Yates CW; Hansen MR
    J Neurosurg; 2023 Apr; 138(4):962-971. PubMed ID: 36087315
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Prospects of Drug Therapy of Vestibular Schwannoma].
    Zhong P
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Jul; 53(4):549-553. PubMed ID: 35871721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.